ArticleBMC oral health2025
Evaluation of survival rate in patients with tongue squamous cell carcinoma: a retrospective single-center study.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The miR-302 family suppresses tumor growth in tongue squamous cell carcinoma by directly targeting P65.Oncogene · 2026Article
- Identification of Critical miRNAs miR-4652 and miR-1304 as Novel Diagnostic Markers for Oral Squamous Cell Carcinoma.Cancer reports (Hoboken, N.J.) · 2026Article
- Southern Iran tertiary-center validation of 5-year disease free survival and overall survival rates in tongue squamous cell carcinoma: a confirmatory retrospective 10-years cohort study.BMC oral health · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe tongue squamous cell carcinoma (TSCC) is a highly prevalent form of oral squamous cell carcinoma with poor prognosis and aggressive behavior. The present study aimed to evaluate the association between tumor grade, clinical stage, and survival outcomes in patients with TSCC.. METHODOLOGY: Patients with a history of having TSCC, complete clinical and demographic data (age and gender), and a through clinical and histopathological follow-up period of six months were included. The overall survival (OS) and disease-free survival (DFS) of the participants were determined.Histopathological grade was assessed as a secondary objective. Kaplan-Meier survival analysis was performed, and data analysis was conducted using the Kaplan-Meier method, log-rank test and a multivariable Cox regression model.
resultsA total number of 162 patients were included with the mean age of 59.6 ± 15.7 years. The majority of the patients (53.1%) were women. Most patients were classified as Grade I (37.7%) and Stage I (46.3%). The local recurrence and metastasis rates were 12.3% and 4.3%, respectively. The median OS and DFS of the patients included 46 ± 7.8 months and 36 ± 5.7 months, respectively. Five-year OS and DFS rates of 41.5% and 36%. No significant correlation was found between OS and DFS with patients' gender or histological grade. However, OS and DFS were inversely related to the clinical stage and age, showing statistical significance (P < 0.05). Additionally, OS was significantly influenced by tumor size, lymph node involvement, and metastasis (P < 0.05). Factors such as tumor size, lymph node involvement, clinical stage, and patient age significantly impacted OS (P < 0.05). In contrast, lymph node involvement, clinical stage, and patient age were significantly associated with DFS (P < 0.05).
conclusionClinical factors including tumor size, lymph node involvement, clinical stage, and patient age were associated with OS. All these variables were also associated with DFS, except for tumor size. The histopathological grade was not influential on OS or DFS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.